+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pneumococcal Vaccine Market by Vaccine Type, Age Group, Route of Administration, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Pneumococcal Vaccine Market by Vaccine Type, Age Group, Route of Administration, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Pneumococcal Vaccine Market by Vaccine Type, Age Group, Route of Administration, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968848
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pneumococcal Vaccine Market is projected to reach USD 13.45 Billion in 2026. It is expected to continue growing at a CAGR of 8.18%, reaching USD 21.67 Billion by 2032.

Pneumococcal vaccines remain a core public health and life sciences priority because Streptococcus pneumoniae causes invasive pneumococcal disease, pneumonia, meningitis, bacteremia, and otitis media across pediatric, adult, and immunocompromised populations. The World Health Organization recommends pneumococcal conjugate vaccines in childhood immunization programs, while the U.S. CDC continues to identify pneumococcal pneumonia as a major cause of adult hospitalization and severe disease among older adults and people with underlying medical conditions.

Market momentum is being shaped by broader-valent pneumococcal conjugate vaccines, adult immunization expansion, national immunization program updates, and rising attention to antimicrobial resistance. As countries evaluate PCV10, PCV13, PCV15, PCV20, PPSV23, and next-generation candidates, success increasingly depends on serotype coverage, real-world effectiveness, affordability, cold-chain execution, programmatic fit, and evidence-based policy adoption.

Transformative Shifts in the Pneumococcal Vaccine Landscape

The pneumococcal vaccine landscape is shifting from childhood-only protection toward life-course immunization. Pediatric programs remain foundational, but aging populations, chronic disease prevalence, and higher clinical risk among adults are elevating demand for adult pneumococcal vaccination. Broader-valent conjugate vaccines are changing competitive dynamics by targeting additional disease-causing serotypes and simplifying schedules in some markets.

Policy and procurement models are also evolving. High-income countries increasingly rely on advisory committee recommendations, real-world effectiveness data, pharmacoeconomic evidence, and post-authorization safety monitoring, while lower- and middle-income countries prioritize Gavi support, pooled procurement, supply reliability, and equitable access. At the same time, serotype replacement, antimicrobial resistance patterns, and regional differences in circulating strains are driving ongoing surveillance and vaccine portfolio diversification.

Cumulative Impact of Artificial Intelligence on Pneumococcal Vaccines

Artificial intelligence is accelerating pneumococcal vaccine development and commercialization by improving antigen selection, serotype surveillance, trial design, demand planning, and manufacturing quality control. AI-enabled genomic analytics can help monitor pneumococcal strain evolution and detect serotype replacement patterns faster than conventional manual approaches, strengthening evidence for vaccine updates and regional targeting.

Across commercialization and public health delivery, AI supports more accurate immunization demand planning, cold-chain risk prediction, adverse event signal detection, provider engagement, and prioritization of high-risk populations. For manufacturers, machine learning can improve yield monitoring, batch consistency, deviation detection, and process analytics in complex conjugate vaccine production. The cumulative impact is a more responsive pneumococcal vaccine ecosystem, though adoption must be governed by validated models, transparent data lineage, cybersecurity controls, privacy safeguards, and regulatory-grade documentation.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is a high-priority region due to large birth cohorts, expanding adult vaccination awareness, and policy modernization in countries such as China, India, Japan, Australia, and South Korea. National immunization decisions vary widely, making local serotype data, pricing, reimbursement design, and manufacturing partnerships central to market access. North America remains a mature and innovation-led region, supported by CDC and NACI guidance, strong pharmacy vaccination infrastructure, electronic immunization records, and rapid adoption of higher-valent adult pneumococcal vaccines.

Latin America benefits from established public immunization systems and PAHO-supported procurement mechanisms, with Brazil and Mexico acting as important demand centers for routine pediatric protection and risk-based adult vaccination. Europe is shaped by national immunization technical advisory groups, EMA-authorized products, health technology assessment, and differentiated adult recommendations across countries. The Middle East, particularly GCC markets, is investing in preventive care and adult immunization as part of healthcare modernization, while Africa remains heavily influenced by donor-supported pediatric vaccine access, cold-chain capacity, health workforce reach, and the need to reduce pneumonia mortality through sustained routine immunization coverage.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets present strong long-term potential as governments strengthen childhood immunization, expand private-sector vaccination, improve disease surveillance, and build regional healthcare capacity; however, affordability, procurement predictability, and cold-chain consistency remain critical. The GCC is moving toward prevention-focused healthcare strategies, creating opportunities for adult pneumococcal vaccination among older adults, people with diabetes, people with chronic respiratory or cardiovascular disease, and other high-risk groups.

The European Union offers a regulated, evidence-driven environment where health technology assessment, budget impact, pharmacovigilance, and serotype epidemiology influence adoption. BRICS countries represent scale and manufacturing opportunity, especially as China, India, and Brazil invest in domestic vaccine capabilities, public-sector immunization reach, and localized regulatory pathways. G7 markets remain primary centers for higher-valent vaccine uptake, real-world evidence generation, adult immunization policy development, and premium access pathways. NATO countries overlap significantly with high-income immunization systems, where pandemic preparedness, resilient supply chains, life-course vaccination, and adult vaccination infrastructure are increasingly strategic priorities.

Key Country Insights Across Major Pneumococcal Vaccine Markets

The United States is a leading pneumococcal vaccine market due to ACIP recommendations, broad retail pharmacy access, Medicare-linked adult vaccination pathways, and strong adult immunization infrastructure, while Canada follows NACI guidance with implementation shaped by provincial and territorial programs. Mexico and Brazil rely on large public immunization systems, with Brazil’s national program and local production ecosystem supporting broad reach. In Europe, the United Kingdom, Germany, France, Italy, and Spain each apply national recommendations that differ by age, risk group, vaccine type, reimbursement approach, and public health budget priorities, while Russia maintains a sizeable immunization environment influenced by domestic policy, epidemiological priorities, and supply considerations.

China is expanding its vaccine ecosystem through growing private demand, regulatory modernization, adult prevention awareness, and domestic innovation, while India combines a large pediatric population with public-sector introduction, affordability requirements, and expanding immunization infrastructure. Japan has well-established elderly vaccination policies and a strong preventive healthcare culture, Australia maintains evidence-based national immunization scheduling and high-quality surveillance systems, and South Korea supports advanced vaccine access through strong healthcare infrastructure, high awareness of adult preventive care, and robust clinical adoption pathways.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize broader-valent conjugate vaccine strategies, robust adult immunization evidence, and differentiated market access plans by country income level, immunization schedule, procurement model, and policy environment. Investment in real-world effectiveness studies, serotype surveillance partnerships, pharmacoeconomic modeling, and post-introduction impact assessments will be essential to demonstrate value beyond pediatric disease prevention.

Manufacturers should strengthen supply resilience through diversified antigen sourcing, scalable conjugation capacity, cold-chain optimization, regional fill-finish partnerships, and quality-by-design manufacturing systems. Commercial and medical teams should align messaging with public health priorities, including antimicrobial resistance reduction, hospital burden mitigation, protection of high-risk adults, and improved routine immunization coverage. AI should be deployed in validated use cases such as demand forecasting, pharmacovigilance, genomic surveillance, and manufacturing analytics, with governance frameworks that meet regulatory, ethical, privacy, and cybersecurity expectations.

Research Methodology

This executive summary is built on secondary research from recognized public health authorities, regulatory agencies, immunization advisory bodies, peer-reviewed clinical literature, and market-facing vaccine policy sources. Core references include WHO pneumococcal vaccine position guidance, CDC and ACIP recommendations, NACI guidance, national immunization schedules, EMA and other regulatory information, and publicly available procurement and immunization program data.

The methodology emphasizes triangulation across epidemiology, vaccine technology, regulatory approvals, reimbursement pathways, public procurement models, adult immunization policy, pediatric schedule adoption, pharmacovigilance, and regional immunization infrastructure. Insights are validated through consistency checks across authoritative sources and are interpreted to support strategic decision-making without relying on unverified market-size, market-share, or forecasting claims.

Conclusion

The pneumococcal vaccine market is entering a new phase defined by higher-valent conjugate products, expanded adult vaccination, AI-enabled surveillance, and stronger evidence requirements for reimbursement and public procurement. Demand is supported by persistent pneumococcal disease burden, aging populations, risk-based vaccination policies, and the global need to reduce antibiotic use and prevent severe respiratory infections.

Organizations that combine scientific differentiation, reliable supply, country-specific access strategies, credible real-world evidence, and strong public health partnerships will be best positioned to capture growth opportunities. The most competitive participants will treat pneumococcal vaccination not only as a pediatric public health intervention but as a life-course prevention platform with measurable clinical, operational, and economic value.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Pneumococcal Vaccine Market, by Vaccine Type
7.1. Conjugate Vaccine
7.1.1. Pcv13
7.1.2. Pcv15
7.1.3. Pcv20
7.2. Polysaccharide Vaccine
8. Pneumococcal Vaccine Market, by Age Group
8.1. Adult
8.2. Children
8.3. Geriatric
9. Pneumococcal Vaccine Market, by Route of Administration
9.1. Subcutaneous
9.2. Intramuscular
10. Pneumococcal Vaccine Market, by End User
10.1. Ambulatory Care Centers
10.2. Clinics
10.3. Hospitals
10.4. Immunization Centers
11. Pneumococcal Vaccine Market, by Distribution Channel
11.1. Offline
11.2. Online
12. Asia-Pacific Pneumococcal Vaccine Market
13. North America Pneumococcal Vaccine Market
14. Latin America Pneumococcal Vaccine Market
15. Europe Pneumococcal Vaccine Market
16. Middle East Pneumococcal Vaccine Market
17. Africa Pneumococcal Vaccine Market
18. ASEAN Pneumococcal Vaccine Market
19. GCC Pneumococcal Vaccine Market
20. European Union Pneumococcal Vaccine Market
21. BRICS Pneumococcal Vaccine Market
22. G7 Pneumococcal Vaccine Market
23. NATO Pneumococcal Vaccine Market
24. United States Pneumococcal Vaccine Market
25. Canada Pneumococcal Vaccine Market
26. Mexico Pneumococcal Vaccine Market
27. Brazil Pneumococcal Vaccine Market
28. United Kingdom Pneumococcal Vaccine Market
29. Germany Pneumococcal Vaccine Market
30. France Pneumococcal Vaccine Market
31. Russia Pneumococcal Vaccine Market
32. Italy Pneumococcal Vaccine Market
33. Spain Pneumococcal Vaccine Market
34. China Pneumococcal Vaccine Market
35. India Pneumococcal Vaccine Market
36. Japan Pneumococcal Vaccine Market
37. Australia Pneumococcal Vaccine Market
38. South Korea Pneumococcal Vaccine Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. Abbott Laboratories
40.2. Astellas Pharma Inc.
40.3. Beijing Minhai Biotechnology Co., Ltd.
40.4. Bharat Biotech International Ltd.
40.5. Biological E. Limited
40.6. BioNTech SE
40.7. GSK plc
40.8. Inventprise LLC
40.9. KM Biologics Co., Ltd.
40.10. LG Chem Ltd.
40.11. Merck & Co., Inc.
40.12. Novartis AG
40.13. Panacea Biotec Ltd.
40.14. Pfizer Inc.
40.15. Pnuvax Incorporated
40.16. Sanofi S.A.
40.17. Serum Institute of India Pvt. Ltd.
40.18. Shenzhen Kangtai Biological Products Co., Ltd.
40.19. SK Bioscience Co., Ltd.
40.20. Vaxcyte Inc.
40.21. Walvax Biotechnology Co., Ltd.
List of Figures
FIGURE 1. GLOBAL PNEUMOCOCCAL VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PNEUMOCOCCAL VACCINE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PNEUMOCOCCAL VACCINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL PNEUMOCOCCAL VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 23. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PNEUMOCOCCAL VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PCV13 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PCV13 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PCV13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PCV15 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PCV15 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PCV15 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PCV20 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PCV20 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PCV20 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL POLYSACCHARIDE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL POLYSACCHARIDE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CHILDREN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CHILDREN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL IMMUNIZATION CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL IMMUNIZATION CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL IMMUNIZATION CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 63. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 64. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 65. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 66. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 67. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 68. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 70. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 71. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 75. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 77. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 78. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 79. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 81. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 84. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 85. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 86. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 87. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 88. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 91. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 92. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 93. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 94. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 96. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 98. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 99. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 100. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 101. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 105. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 106. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 107. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 110. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 112. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 113. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 114. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 115. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 117. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 119. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 120. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 121. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 122. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 123. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 124. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 126. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 127. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 128. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 129. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 133. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 134. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 135. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 136. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 140. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 141. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 142. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 146. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 147. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 148. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 149. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 150. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 151. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 153. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 154. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 155. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 156. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 157. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 159. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 160. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 161. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 162. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 163. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 164. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 167. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 168. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 169. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 170. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 171. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 172. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 174. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 175. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 176. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 177. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 181. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 182. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 183. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 184. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 185. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 186. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 187. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 188. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 189. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 190. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 191. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 192. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 195. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 196. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 197. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 198. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 201. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 202. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 203. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 204. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 205. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 206. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 207. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 208. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 209. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 210. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 211. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 212. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 213. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 214. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 215. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 216. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 217. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 218. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 219. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 220. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 222. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 223. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 224. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 225. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 226. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 227. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 230. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 231. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 232. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 233. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 234. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 235. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 236. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 237. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 238. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 239. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 240. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 241. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 242. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 243. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 244. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 245. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
TABLE 246. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 247. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 248. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 249. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Pneumococcal Vaccine market report include:
  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Beijing Minhai Biotechnology Co., Ltd.
  • Bharat Biotech International Ltd.
  • Biological E. Limited
  • BioNTech SE
  • GSK plc
  • Inventprise LLC
  • KM Biologics Co., Ltd.
  • LG Chem Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Pnuvax Incorporated
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • SK Bioscience Co., Ltd.
  • Vaxcyte Inc.
  • Walvax Biotechnology Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages181
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 13.45 Billion
Forecasted Market Value ( USD ) by 2032 $ 21.67 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned22

Related Topics

Related Reports

Pneumococcal Vaccine Market Report and Forecast 2025-2034 - Product Image

Pneumococcal Vaccine Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Pneumococcal Vaccine Market Size, Share, Trends and Forecast by Vaccine Type, Product Type, Distribution Channel, End User, and Region, 2026-2034 - Product Image

Pneumococcal Vaccine Market Size, Share, Trends and Forecast by Vaccine Type, Product Type, Distribution Channel, End User, and Region, 2026-2034

  • Report
  • 135 Pages
  • Global
From
Pneumococcal Vaccine Market Report 2026 - Product Image

Pneumococcal Vaccine Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Pneumococcal Vaccine Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Pneumococcal Vaccine Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 85 Pages
  • Global
From
Pneumococcal Vaccines Market - Global Strategic Business Report - Product Image

Pneumococcal Vaccines Market - Global Strategic Business Report

  • Report
  • 285 Pages
  • Global
From

About the Pneumococcal Vaccine Market

The Pneumococcal Vaccine is a type of vaccine used to protect against infection caused by the bacterium Streptococcus pneumoniae. It is used to prevent a range of illnesses, including pneumonia, meningitis, and sepsis. The vaccine is typically administered to infants and young children, as well as adults who are at an increased risk of infection. It is also recommended for adults over the age of 65. The Pneumococcal Vaccine market is a subset of the larger Vaccines market. It is a highly competitive market, with a number of companies offering different types of vaccines. These companies are typically involved in the research, development, and production of the vaccines. They also provide support services such as distribution, marketing, and education. Some of the companies in the Pneumococcal Vaccine market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.